EC
CLDX icon

EcoR1 Capital’s Celldex Therapeutics CLDX Stock Holding History

EcoR1 Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-650,000
Closed -$22.1M – 62
2024
Q3 		$22.1M Hold
650,000
– – 0.76% 31
2024
Q2 		$24.1M Hold
650,000
– – 0.74% 29
2024
Q1 		$27.3M Buy
+650,000
New +$26.7M 0.69% 27

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EcoR1 Capital's CLDX Position: Q4 2024 in Review

EcoR1 Capital sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 650,000 shares — an estimated $22.1M sold.

EcoR1 Capital first reported a position in CLDX in Q1 2024 and held it in 3 quarters. The position peaked at $27.3M in Q1 2024. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • EcoR1 Capital reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • EcoR1 Capital sold 650,000 Celldex Therapeutics shares in Q4 2024, an estimated $22.1M.
  • EcoR1 Capital first reported a position in Celldex Therapeutics in Q1 2024 and held it in 3 quarters.
  • EcoR1 Capital's Celldex Therapeutics position peaked at $27.3M in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on EcoR1 Capital's 13F filing for Q4 2024, filed 14 Feb 2025.